Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer | Zendy

Yıldız Okuturlar | Zendy; Meral Günaldı | Zendy; Hakan Koçoğlu | Zendy; Mehmet Hurşitoğlu | Zendy; Asuman Gedikbaşı | Zendy; Didem Acarer | Zendy; Özlem Harmankaya | Zendy; Abdülbaki Kumbasar | Zendy

Open Access

Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer

Author(s) -

Yıldız Okuturlar,

Meral Günaldı,

Hakan Koçoğlu,

Mehmet Hurşitoğlu,

Asuman Gedikbaşı,

Didem Acarer,

Özlem Harmankaya,

Abdülbaki Kumbasar

Publication year - 2018

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.235355

Subject(s) - arylesterase , medicine , breast cancer , receiver operating characteristic , gastroenterology , chemotherapy , paraoxonase , cancer , oncology , biology , genotype , biochemistry , oxidative stress , pon1 , gene

The aims of this study are to evaluate the serum levels of paraoxonase (PON) and arylesterase (ARE) in breast cancer (BC) patients; to determine their relationship with chemotherapy requirements in BC; and to find a cut-off value to assess subjects with a higher risk of BC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research